Company Profile
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest News
Twist Bioscience (TWST) Stock Looks Overvalued Even With Strong Growth Hopes
Cathie Wood buys $50.1 million of tumbling megacap stock
Twist Bioscience (TWST) Surged on Strong Results and AI Drug Discovery Demand
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Website | https://www.twistbioscience.com |
| Audit Risk | 1 |
| Board Risk | 7 |
| Overall Risk | 8 |
| Market Cap | 5.62B |
| Forward P/E | -106.2 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -1.32 |
| Forward EPS | -0.85 |
| Book Value | 7.32 |
| Price-to-Book | 12.33 |
| Enterprise-to-Revenue | 13.58 |
| Enterprise-to-EBITDA | -50.63 |
| Short Ratio | 6.88 |
| Earnings Date | 08/03/2026 |
| Earnings Call Date | 08/03/2026 |
| Earnings Average | -0.18 |
| Earnings Low | -0.2 |
| Earnings High | -0.16 |
| Revenue Average | 114.54M |
| Revenue Low | 114.00M |
| Revenue High | 115.00M |